Alira Health Welcomes Nikole Siegmund, Vice President, Preclinical

News
Published on:
March 15, 2021

BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is pleased to announce that Nikole Siegmund has joined the firm as Vice President, Preclinical Development. Nikole joins the team with an expansive preclinical background serving the pharmaceutical industry and Clinical Research organizations (CRO) and is based out of Alira Health’s headquarters in Framingham, Massachusetts.

“It is an honor to have Nikole join Alira Health’s Product Development team to accelerate our business development efforts and manage our preclinical offerings, “ said Dr. Mitchell Sanders, Chief Scientific Officer. “Nikole’s wealth of experience in preclinical models, operations, and project management helps us expand our preclinical lab services in oncology, liver and metabolic disease, wound care, and surgery.

“I am excited to join the Alira Health team of dedicated professionals who work tirelessly to improve the healthcare industry and patient care,” said Nikole. “I look forward to working alongside our clients, developing, and improving technologies in the pre-clinical space, and further advancing patient care around the globe.”

Nikole brings over 20 years of preclinical experience in the CRO and pharmaceutical spaces. She is an experienced Vice President of Operations with a proven history of working in both large and small organizations.

Prior to Alira Health, Nikole worked with Woodland Pharmaceuticals LLC and has experience in oncology, NASH and metabolic diseases, PK/PD, Good Laboratory Practice (GLP), Data QC, and business development. She currently serves as a voting member of the Tufts University and Tufts Medical Center Institutional Animal Care and Use Committee.

Related news

Due Diligence Research & Development
Publications August 18, 2021
Infographic: Indication Prioritization and Pre-Commercial Value Assessment
Download our infographic on Indication Prioritization and Pre-Commercial Value Assessment.
Research & Development
Events August 8, 2021
Event: BioProcess International
Join Alira Health at BioProcess International on September 20-23, 2021.
Pharma Research & Development
Publications August 2, 2021
Infographic: Prioritization Strategy of R&D Targets for Biotech Company
Download our infographic on Prioritization Strategy of R&D Targets for Biotech Company
Research & Development
Publications June 9, 2021
EU Supply Integrity Guidelines
Check out Alira Health's latest publication, “EU Supply Integrity Guidelines”. In the document, best practices for European distribution and supply integrity management are highlighted(...)
Research & Development
Publications May 27, 2021
Buffers – Navigating New Demands On Downstream Raw Materials
The COVID-19 pandemic has put unusual pressures on the supply and demand of raw materials required for the production and purification of biologics. A specific concern for the biomanufacturing(...)
Research & Development
Publications April 26, 2021
Recombinant Human Polyclonal Antibodies to Treat Disease
Congratulations to Alira Health’s Steven Chamow, PhD, Senior Vice President, CMC and founder of Chamow & Associates, and to Bryan Monroe and Chuck Olson, Senior Consultants, on their(...)
Research & Development
Publications March 9, 2021
A Primer on Potency Assays for Release of Biologics
A key criterion in determining the quality of a biologic product is whether it has maintained its biological activity or “potency.”

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.